Fabino Life Sciences (BOM:543444) LT-Debt-to-Total-Asset : 0.08 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Fabino Life Sciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Fabino Life Sciences's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.08.

Fabino Life Sciences's long-term debt to total assets ratio increased from Mar. 2023 (0.08) to Mar. 2024 (0.08). It may suggest that Fabino Life Sciences is progressively becoming more dependent on debt to grow their business.

Fabino Life Sciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for Fabino Life Sciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fabino Life Sciences LT-Debt-to-Total-Asset Chart

Fabino Life Sciences Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.30

0.14

0.01

0.08

Fabino Life Sciences Semi-Annual Data
	Mar19	Mar20	Mar21	Mar22	Sep22	Mar23	Sep23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial			0.01	0.01	0.08	0.14	0.08

Fabino Life Sciences LT-Debt-to-Total-Asset Calculation

Fabino Life Sciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	12.691	/	153.568
	=	0.08

Fabino Life Sciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	12.691	/	153.568
	=	0.08

Fabino Life Sciences (BOM:543444) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Fabino Life Sciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Fabino Life Sciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Fabino Life Sciences (BOM:543444) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fabino Life Sciences Ltd (BOM:543444) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

Murthal Road,, Shubham Garden, Jeevan Vihar Extension Near, Sonipat, HR, IND, 131001

Website

https://www.fabinolife.com

Fabino Life Sciences Ltd is a pharmaceutical company. It is engaged in manufacturing, marketing, trading and packing of pharmaceutical and other wellness-focused consumer products. It offers a wide range of allopathic, Food and wellness, Veterinary, Multi-vitamin and herbal products. The company currently supplies in Haryana, Delhi, parts of Punjab, Himachal Pradesh, Eastern Uttar Pradesh, Orissa, and Jharkhand, and parts of West Bengal, Andhra Pradesh, and Nepal.

Fabino Life Sciences (BOM:543444) Headlines

No Headlines